Projects funded by the Dementia Consortium
Modulation of CSF1R: a promising strategy to control neuroinflammati
Target - CSF1R-IL34

The contribution of ARUK, CRO and Industry partners was optimal. We were lucky to form a very productive collaboration… As a collaboration with a translational objective, this has been the most positive and productive experience I’ve had so far.
Dr Diego Gomez-Nicola, University of Southampton
ALS disease models and therapeutic drug screen
Target - TDP-43

The Dementia Consortium has been essential in bringing my academic research to a level that would now be considered by companies working in early drug discovery. This has been done not only by providing the funding but as importantly creating and facilitating a network of collaborators that have contributed with ideas, expertise and project management
Dr Marco Baralle, International Centre for Genetics Engineering and Biotechnology, Italy
The role of P2Y6R in mice in cognition, neuronal loss and tauopathy
Target - P2Y6
![P2Y6R_Guy Brown The Dementia Consortium project provided…invaluable expertise and advice in translation and drug development…[the] hands-on expertise of the Dementia Consortium team was invaluable](https://dementiaconsortium.org/wp-content/uploads/bb-plugin/cache/P2Y6R_Guy-Brown-circle.jpg)
The Dementia Consortium project provided…invaluable expertise and advice in translation and drug development…[the] hands-on expertise of the Dementia Consortium team was invaluable
Prof Guy Brown, University of Cambridge
Developing novel small molecules as effective inhibitors of the NLRP3 inflammasome
Target - NLRP3

The grant employed a postdoc in Manchester for a short period. We were able to achieve a publication which helps career development
Prof David Brough, University of Manchester
Validating TTBK1 as a target for AD: TTBK1 knock-down and small molecule inhibitor approaches
Target - TTBK1

We would like to express our sincere gratitude for the opportunity to participate in the Dementia Consortium collaboration. The input of the funding partners based on their experience in drug discovery is very important and will be a benchmark for us in the future
Prof Tsuneya Ikezu, Boston University
The project tested the hypothesis that supressing TTBK1 could prevent progression of AD through suppression of pTau accumulation and associated neuroinflammation.
CLPP-dependent activation of mitochondria quality control signalling in neurodegenerative diseases
Target - CLPP

The project benefited from the DC framework by regular meetings with ARUK and the research partner and updates with the industry partners. These meetings facilitate thorough analysis of the data and support decision making for follow-up steps
Dr Nicoleta Moisoi, De Montfort University
ER-mitochondria signalling as a new target for Dementia (VAPB-PTPIP51 tethering)
Target - VAPB-PTPIP51

The input from members was intrinsic in developing the core structure of the project. Moreover, the expertise in drug discovery by consortium members and by EVOTEC scientists has been essential for progress on this crucial component of the project. We do not have such skills with our academic collaborators.
Prof Chris Miller, King’s College London
The aim of this project is to confirm the hypothesis that damage to the endoplasmic reticulum (ER) mitochondria signalling via loss of the interaction between the VABP and PTPIP51 (ER-mitochondrial tethers), is a driver of early pathology in FTD/ALS with relevance also to Alzheimer’s disease and Parkinson’s disease.
Identification of tool compounds targeting the SRSF1-dependent nuclear export of pathological C9ORF72-repeat transcripts
Target - C9ORF72
![Dr Tennore Ramesh & Guillaume Hautbergue This model of bringing in industry partners to complement academic work has many benefits. [It allows]… independent validation of project by industrial and academic researchers. This is especially critical in this time where data reproducibility is at an all-time low.](http://dementiaconsortium.org/wp-content/uploads/2022/02/Dr-Tennore-Ramesh-Guillaume-Hautbergue.png)
This model of bringing in industry partners to complement academic work has many benefits. [It allows]… independent validation of project by industrial and academic researchers. This is especially critical in this time where data reproducibility is at an all-time low.